Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study to Evaluate the Safety and Pharmacokinetics of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Neonates Exposed to HIV-1

NCT07055451 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT07055451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07055451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study to Evaluate the Safety and Pharmacokinetics of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Neonates Exposed to HIV-1
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 12, 2025
Completion date
March 31, 2028
Enrollment
16 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection